GGrantIndex
Sort

48,018 grants matching immunotherapy

Breaking down tumor immune privilege through targeted hypoxia reduction

$481,691
Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

NCI Moonshot: Pediatric Core

$481,675
Leonard Freedman · Leidos Biomedical Research, Inc. · N01 · FY2019 · CA

Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma

$481,659
Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA

NIH Chronic GVHD Study Group

$481,641
Steven Pavletic · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors

$481,578
Seth M Pollack · Northwestern University At Chicago · R01 · FY2023 · CA

Generating CTL Against Tumor Associated Peptide Antigens

$481,518
Linda A Sherman · Scripps Research Institute, The · R01 · FY2007 · CA

Renalase inhibition for treatment of unresectable melanoma

$481,477
Harriet M Kluger · Yale University · R01 · FY2021 · CA

Targeting HSP70 for Melanoma Therapy

$481,458
Maureen E Murphy · Wistar Institute · P01 · FY2019 · CA

Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection

$481,406
Elina I Zuniga · University Of California, San Diego · R01 · FY2021 · AI

Fecal Microbiota Transplant and PD-1 blockade in Melanoma

$481,349
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA

JAML: A New Costimulatory Molecule for Gamma Delta T Cells

$481,250
Wendy L Havran · Scripps Research Institute, The · R01 · FY2016 · AI

Enhancing the Immunogenicity of Recombinant MVA Vectors

$481,191
Emory University · U19 · FY2004 · AI

Project 1: FLASH vs. Standard radiotherapy for treatment of PDAC and sparing normal intestine tissues

$481,131
Constantinos Koumenis · University Of Pennsylvania · P01 · FY2022 · CA

Regulation of encephalitogenic T cells by CRAC channels

$481,126
Stefan Feske · New York University School Of Medicine · R01 · FY2018 · AI

Investigating the Genesis of Tumor Immune Microenvironment (TIME) as a function of Inflammation

$481,066
Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2025 · CA

Image guided immunotherapy and targeted radionuclide therapy of metastatic melanoma

$481,065
Carolyn J Anderson · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA

Targeting PPT1 in the Tumor Microenvironment

$480,986
Ravi K Amaravadi · Wistar Institute · P01 · FY2022 · CA

Developing newly combined therapeutic strategies for mature B cell lymphoma

$480,946
Jing Hong Wang · University Of Colorado Denver · R01 · FY2019 · CA

Membrane-based immunotherapy for triple negative breast cancer- a partnered approach

$480,895
Periasamy Selvaraj · Emory University · R01 · FY2020 · CA

Gonorrhea and HIV prevention with intravaginal ring drug delivery

$480,773
Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R33 · FY2020 · AI

Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection

$480,770
Elina I Zuniga · University Of California, San Diego · R01 · FY2020 · AI

Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer

$480,760
Ralph P Mason · Ut Southwestern Medical Center · R01 · FY2023 · CA

Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors

$480,710
Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2022 · CA

Data Management and Analysis Core

$480,706
Aris Floratos · Columbia University Health Sciences · U19 · FY2019 · AI

Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer

$480,703
Hidayatullah G Munshi · Northwestern University At Chicago · R01 · FY2023 · CA